GB2499480A - Method for preserving alum adjuvants and alum-adjuvanted vaccines - Google Patents

Method for preserving alum adjuvants and alum-adjuvanted vaccines Download PDF

Info

Publication number
GB2499480A
GB2499480A GB1216472.9A GB201216472A GB2499480A GB 2499480 A GB2499480 A GB 2499480A GB 201216472 A GB201216472 A GB 201216472A GB 2499480 A GB2499480 A GB 2499480A
Authority
GB
United Kingdom
Prior art keywords
alum
preserving
adjuvants
adjuvanted vaccines
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GB1216472.9A
Other languages
English (en)
Other versions
GB201216472D0 (en
Inventor
Jeffrey Drew
David Woodward
Amanda Corteyn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stabilitech Ltd
Original Assignee
Stabilitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1005518.4A external-priority patent/GB201005518D0/en
Priority claimed from GBGB1005522.6A external-priority patent/GB201005522D0/en
Application filed by Stabilitech Ltd filed Critical Stabilitech Ltd
Publication of GB201216472D0 publication Critical patent/GB201216472D0/en
Publication of GB2499480A publication Critical patent/GB2499480A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
GB1216472.9A 2010-03-31 2011-03-31 Method for preserving alum adjuvants and alum-adjuvanted vaccines Withdrawn GB2499480A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1005518.4A GB201005518D0 (en) 2010-03-31 2010-03-31 Preservation of alum-adjuvanted vaccines
GBGB1005522.6A GB201005522D0 (en) 2010-03-31 2010-03-31 Method for preserving alum-adjuvanted vaccines
PCT/GB2011/000497 WO2011121305A2 (en) 2010-03-31 2011-03-31 Method for preserving alum adjuvants and alum-adjuvanted vaccines

Publications (2)

Publication Number Publication Date
GB201216472D0 GB201216472D0 (en) 2012-10-31
GB2499480A true GB2499480A (en) 2013-08-21

Family

ID=43971221

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1216472.9A Withdrawn GB2499480A (en) 2010-03-31 2011-03-31 Method for preserving alum adjuvants and alum-adjuvanted vaccines

Country Status (13)

Country Link
US (1) US9101607B2 (enExample)
EP (1) EP2552410B1 (enExample)
JP (1) JP6023696B2 (enExample)
KR (1) KR101819250B1 (enExample)
CN (1) CN102892409B (enExample)
AU (1) AU2011234268B2 (enExample)
BR (1) BR112012025044A2 (enExample)
CA (1) CA2795050C (enExample)
DK (1) DK2552410T3 (enExample)
ES (1) ES2708989T3 (enExample)
GB (1) GB2499480A (enExample)
HU (1) HUE042330T2 (enExample)
WO (1) WO2011121305A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011121306A1 (en) * 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles
JP5869553B2 (ja) 2010-03-31 2016-02-24 スタビリテック リミテッド ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
WO2015157637A1 (en) * 2014-04-11 2015-10-15 Surmodics Ivd, Inc. Compositions and methods for in vitro diagnostic tests including zwitterionic solubilization reagent
GB201406569D0 (en) * 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
GB2562241B (en) * 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CN113750228B (zh) * 2021-09-25 2024-02-20 大连理工大学 一种冷冻保护剂在铝佐剂中的应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0130619A2 (en) * 1983-07-05 1985-01-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Hepatitis B vaccine and method for its preparation
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
WO2001093829A2 (en) * 2000-06-08 2001-12-13 Powderject Vaccines, Inc. Powder compositions
WO2005042029A2 (en) * 2003-10-27 2005-05-12 Psma Development Company, Llc Psma formulations and uses thereof
WO2007138135A1 (es) * 2006-05-26 2007-12-06 Instituto Científico Y Tecnológico De Navarra, S.A. Nanopartículas bioadhesivas para la administración de moléculas biológicamente activas
WO2008118691A2 (en) * 2007-03-22 2008-10-02 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
WO2009015343A2 (en) * 2007-07-25 2009-01-29 Bioe, Inc. Differentiation of multi-lineage progenitor cells to chondrocytes

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927208A (en) 1973-05-14 1975-12-16 Rit Rech Ind Therapeut Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them
US4631189A (en) 1980-03-10 1986-12-23 Da Vinci Laboratories, a division of FoodScience Corporation N,N-dimethylglycine and use in immune response
JPS60193925A (ja) 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
JPS61189228A (ja) 1985-02-19 1986-08-22 Nippon Sekijiyuujishiya 血液凝固第８因子製剤の製法
US4950596A (en) 1985-03-04 1990-08-21 The Dow Chemical Company Stabilization of intracellular enzymes
JPS6238173A (ja) 1985-08-13 1987-02-19 三菱レイヨン株式会社 抗血液凝固剤
US5169758A (en) 1986-05-02 1992-12-08 Boehringer Mannheim Gmbh Stabilized, NAD(P)H-dependent, soluble nitrate reductase, a process for the preparation thereof and a reagent containing it
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
EP0303746B2 (en) * 1987-08-21 1998-12-02 Mallinckrodt Group Inc. Stabilization of growth promoting hormones
GB8826429D0 (en) 1988-11-11 1988-12-14 Univ Leeds Ind Service Ltd Enzyme stabilisation systems
DE69032102T2 (de) 1989-08-15 1998-06-25 Massachusetts Inst Technology Stabilisierte impfstoffzusammensetzungen
AU650045B2 (en) 1990-09-12 1994-06-09 Lifecell Corporation Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
GB9521806D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Preservation methods
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
AU707186B2 (en) 1997-07-01 1999-07-01 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
AU5459698A (en) 1997-11-26 1999-06-15 Universal Preservation Technologies, Inc. Preservation of sensitive biological samples by vitrification
EP1133316B1 (en) 1998-11-16 2009-01-21 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
AUPQ347199A0 (en) 1999-10-15 1999-11-11 Csl Limited Novel polypeptide fragments
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US20040110267A1 (en) 2000-12-15 2004-06-10 Stratagene Room temperature stable competent cells
AU2002302814A1 (en) 2001-06-08 2002-12-23 Powderject Vaccines, Inc. Spray freeze-dried compositions
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
JP4936618B2 (ja) 2001-09-21 2012-05-23 株式会社ノエビア 微細エマルション組成物
EP3210624A1 (en) 2002-02-27 2017-08-30 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
WO2004002534A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Use of dimethyl sulfone as isotonicity agent
WO2004007537A2 (en) 2002-07-10 2004-01-22 Transgene S.A. Modified adenoviral fiber with ablated to cellular receptors
AU2003272174A1 (en) 2002-10-21 2004-05-04 Biotage Ab Use of osmolytes to heat stabilise luciferase and/or apyrase
MXPA05006147A (es) 2002-12-10 2005-08-26 Schering Plough Ltd Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US7642077B2 (en) 2003-12-08 2010-01-05 Genencor International, Inc. Biocomposite comprising co-precipitate of enzyme, silicate and polyamine
EP1711619A4 (en) 2003-12-30 2007-04-11 Virumar Pituach Tarkivin Ltd INTEGRATED VIRUS COMPLEXES, METHOD FOR THE MANUFACTURE THEREOF, VACCINES CONTAINING THEM AND METHOD FOR THE USE THEREOF
BRPI0508440A (pt) 2004-03-03 2007-07-24 Revance Therapeutics Inc composições e métodos para diagnóstico tópico e transporte terapêutico
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
MX2007003968A (es) 2004-10-01 2008-03-04 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
PA8661401A1 (es) 2005-01-28 2006-09-08 Wyeth Corp Formulaciones del liquido polipeptido estabilizado
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
AU2006249640C1 (en) 2005-04-08 2016-10-13 Coimmune, Inc. Dendritic cell compositions and methods
EP2324850A1 (en) 2005-10-04 2011-05-25 Alk-Abelló A/S Solid vaccine formulation
KR101357685B1 (ko) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
SI1961761T1 (sl) 2005-11-30 2010-12-31 Int Inst Cancer Immunology Inc Nove peptidne spojine iz Wilmsovega tumorja
US9393215B2 (en) 2005-12-02 2016-07-19 Novartis Ag Nanoparticles for use in immunogenic compositions
WO2007095337A2 (en) 2006-02-15 2007-08-23 Imclone Systems Incorporated Antibody formulation
US20090047255A1 (en) 2006-11-03 2009-02-19 Alphavax, Inc. Alphavirus and Alphavirus Replicon Particle Formulations and Methods
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
EP2150537A4 (en) * 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
US20090123436A1 (en) 2007-11-08 2009-05-14 Surmodics, Inc. Cryopreservative compositions and methods
AU2009295623A1 (en) 2008-09-24 2010-04-01 Stabilitech Ltd Method for preserving polypeptides using a sugar and polyethyleneimine
US20110212127A1 (en) 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
CN101670104A (zh) 2009-09-24 2010-03-17 浙江大学 一种含人参皂甙的油佐剂及其制备方法
WO2011121306A1 (en) 2010-03-31 2011-10-06 Stabilitech Ltd. Stabilisation of viral particles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0130619A2 (en) * 1983-07-05 1985-01-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Hepatitis B vaccine and method for its preparation
WO1995011700A1 (en) * 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
WO2001093829A2 (en) * 2000-06-08 2001-12-13 Powderject Vaccines, Inc. Powder compositions
WO2005042029A2 (en) * 2003-10-27 2005-05-12 Psma Development Company, Llc Psma formulations and uses thereof
WO2007138135A1 (es) * 2006-05-26 2007-12-06 Instituto Científico Y Tecnológico De Navarra, S.A. Nanopartículas bioadhesivas para la administración de moléculas biológicamente activas
WO2008118691A2 (en) * 2007-03-22 2008-10-02 The Regents Of The University Of Colorado Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
WO2009015343A2 (en) * 2007-07-25 2009-01-29 Bioe, Inc. Differentiation of multi-lineage progenitor cells to chondrocytes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Colloids and Surfaces A: Physicochemical and Engineering Aspects, vol. 339, no. 1-3, 2009, L. Wolff et al., "Comparative stability study of lyophilised aluminium hydroxide adjuvanted vaccine formulations containing a monoclonal antibody as a model antigen and methods used...", pp. 82-93 *

Also Published As

Publication number Publication date
JP6023696B2 (ja) 2016-11-09
US9101607B2 (en) 2015-08-11
EP2552410A2 (en) 2013-02-06
WO2011121305A3 (en) 2011-11-24
KR20130012956A (ko) 2013-02-05
HUE042330T2 (hu) 2019-06-28
BR112012025044A2 (pt) 2016-06-21
KR101819250B1 (ko) 2018-01-16
AU2011234268B2 (en) 2015-07-02
ES2708989T3 (es) 2019-04-12
WO2011121305A2 (en) 2011-10-06
EP2552410B1 (en) 2018-10-24
GB201216472D0 (en) 2012-10-31
CA2795050A1 (en) 2011-10-06
US20130156797A1 (en) 2013-06-20
JP2013523705A (ja) 2013-06-17
CA2795050C (en) 2018-05-22
CN102892409B (zh) 2015-12-09
AU2011234268A1 (en) 2012-09-27
CN102892409A (zh) 2013-01-23
DK2552410T3 (en) 2019-02-18

Similar Documents

Publication Publication Date Title
WO2011121305A3 (en) Method for preserving alum adjuvants and alum-adjuvanted vaccines
GB201216469D0 (en) Stabilisation of viral particles
GB201117233D0 (en) Stabilisation of polypeptides
CY1118478T1 (el) Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου για τη θεραπεια του πονου
AP2013006816A0 (en) Ptocess for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation
MY183312A (en) Pharmaceutical formulation
WO2014195978A3 (en) PROCESS FOR THE PREPARATION OF (3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL-AMINO)-ß-OXO-1-PIPERIDINEPROPANENITRILE AND ITS SALTS
CL2014000762A1 (es) Uso de particulas de un ingrediente alimenticio absorbente de agua insoluble como un portador para el agua y/o un humectante, porque sirve para la introduccion de agua en un producto de chocolate; agente de tropicalizacion; producto de chocolate tropicalizado; metodo para la preparacion de dicho agente; y metodo para mejorar la estabilidad al calor
PH12012502216A1 (en) Pharmaceutical formulations comprising 1-(beta-d-glucopyranosyl)-2-thienyl-methylbenzene derivatives as inhibitors of sglt
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
GB201301596D0 (en) Method and system for pacing, ack'ing, timing, and handicapping (path) for simultaneous receipt of documents
SI2629792T1 (sl) Postopek shranjevanja aluminijevega adjuvansa, ki vsebuje sestavek cepiva
NZ605444A (en) Salt and solvates of a tetrahydroisoquinoline derivative
WO2012071369A3 (en) A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2013006569A3 (en) Herpes virus vaccine and methods of use
EA201170983A1 (ru) Производные тиадиазолов и оксадиазолов, их получение и их применение в терапии
MX384120B (es) Composiciones de vacuna.
PH12014500274A1 (en) Use of chitosans to increase nail growth rate
CY1118079T1 (el) Μεθοδος παρασκευης του αλατος l-αργινινικης περινδοπριλης
WO2011080271A3 (en) Exosomes derived from reticulocytes infected with plasmodium sp., method for obtaining them and uses thereof
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1
IT1403282B1 (it) Procedimento per la preparazione di linagliptin
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
ITBS20100012A1 (it) Procedimento per la preparazione di fluazinam
IT1405996B1 (it) Procedimento per la preparazione di 2,5-diaminotoluolo

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)